Tag Archives: cancer

Background Atrial fibrillation (AF) occurs at an increased frequency in patients with cancer, however, the link between cancer and AF is not fully understood.1,2 Stroke prophylaxis with anticoagulation is important; however, this can prove challenging in the setting of active malignancy, which predisposes to an increased risk of haemorrhage, as well as thrombosis.3 Traditionally, low molecular weight heparin (LMWH) and warfarin have been used in this setting. There remains limited evidence for direct oral anticoagulants (DOACs) in cancer patients for stroke prophylaxis in AF (SPAF). However, small observational studies have demonstrated compa

To address this urgent need, the International Society for Thrombosis and Haemostasis (ISTH) is providing open access to its COVID-19 resource page via the ISTH Academy, as well as making all content from the ISTH Academy freely accessible. To access all ISTH content, simply visit academy.isth.org and sign in with your ISTH log-in or create a free ISTH Academy account to get started. On the ISTH Academy, you can access the latest education and resources from experts in the field around the world. In addition to courses on topics like venous thrombosis and cancer-associated thrombosis, you can also access past meeting presentations, posters, w

As discussed by Findlay and colleagues, ICI-related myocarditis is rare but potentially fatal. Its true incidence remains unknown but data from a single cancer registry study from the USA suggests a prevalence of 1.14% with fatality rates as high as 50%.4,5 Data suggest that myocarditis is an early ICI-toxicity, typically seen within the first three months of starting treatment, and is more common in patients treated with combination anti-CTLA-4 and anti-PD1 blockade. The prevalence of myocarditis in patients treated with chemotherapy and anti-PD1 or tyrosine kinase Inhibitors (TKI) and anti-PD1 combinations has not been described. Identifyin

(more…)

Case A 63-year-old woman presented with breathlessness for a week. She had had a right mastectomy and axillary node clearance three weeks previously for breast cancer. She was known to have rheumatic heart disease and mitral stenosis with history of balloon mitral valvuloplasty 12 years ago. An echocardiogram, which was performed four months before, showed moderate mitral stenosis with valve area of 1.2 cm2, moderate aortic stenosis with peak gradient across aortic valve of 42 mmHg and mean of 22 mmHg and mild tricuspid regurgitation with normal pulmonary artery pressure. She was also known to have permanent atrial fibrillation and was on w

CORONARY: off-pump and on-pump CABG similar The largest trial ever to compare off-pump and on-pump coronary artery bypass surgery (CABG) has shown no difference between the two techniques in terms of the primary composite end point. There were, however, some differences in certain end points, leading to the suggestion that the decision as to which approach to choose could be individualised with each patient. Table 1. Main results from the CORONARY trial The CORONARY trial enrolled 4,752 patients who were randomised to off-pump or on-pump surgery. At 30 days the primary end point – a composite of death, myocardial infraction (MI), kidney fai